Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?
Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?
First reported by Yahoo Finance.
More from Stocks
See all- Stocks
OpenAI's latest AI revelation is a 'serious situation,' Microsoft's Suleyman tells CNBC
Suleyman joined "Squawk Box" to discuss OpenAI's latest incidents of "concerning model behavior" disclosed earlier this week.
- Stocks
Swiss sports brand On signs Kylian Mbappé in blow to Nike
Group targets long-term partnership with French star, similar to relationship with tennis great Roger Federer…